<DOC>
	<DOCNO>NCT01949909</DOCNO>
	<brief_summary>P27A study design randomized phase Ia/Ib trial evaluate safety immunogenicity blood stage candidate vaccine P27A P. falciparum - P27A antigen associate adjuvant ( Alhydrogel GLA-SE ) - malaria non expose European volunteer ( Switzerland ; phase Ia ) malaria expose African volunteer ( Tanzania ; phase Ib ) .</brief_summary>
	<brief_title>Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Phase Ia Inclusion criterion : 1 . Healthy volunteer age 1845 year 2 . General good health base history clinical examination 3 . Written inform consent obtain study procedure 4 . Female volunteer practice contraception 13 week last immunisation 5 . Available participate followup duration study ( 34 week ) 6 . Reachable phone whole study period Phase Ib inclusion criterion 1 . Healthy male volunteer age 1845 year 2 . General good health base history clinical examination 3 . Written inform consent obtain study procedure 4 . Available participate followup duration study ( 34 week ) 5 . Reachable phone whole study period 6 . Having always live area low malaria transmission Phase Ia Exclusion criterion : 1 . Positive pregnancy test females 2 . Actively breast feed female 3 . Previous participation malaria vaccine trial 4 . Symptoms , physical sign laboratory value suggestive systemic disorder , include renal , hepatic , cardiovascular , pulmonary , skin , immunodeficiency , psychiatric condition , could interfere interpretation trial result compromise health volunteer 5 . Any clinically significant laboratory abnormality screen blood sample beyond normal range , define clinical trial site 6 . Enrolment clinical trial whole trial period 7 . Intake chronic medication , especially immunosuppressive agent ( steroid , immunomodulating immunosuppressive drug ) 13 week precede screen visit trial period except topical inhaled steroid 8 . Volunteers unable closely follow social , geographic psychological reason 9 . Previous history drug alcohol abuse interfere normal social function period one year prior enrolment study 10 . Known hypersensitivity vaccine component ( adjuvant peptide ) 11 . Vaccination infusion gammaglobulin 4 week prior first vaccination 6 week third vaccination 12 . Any history malaria 13 . History live malaria endemic area five ( 5 ) year OR live malaria endemic area early childhood . For practical purpose , region malaria chemoprophylaxis advise travel clinic consider malaria endemic ( cf . www.safetravel.ch ) . 14 . Known exposure malaria previous six ( 6 ) month , define visit malaria endemic region 15 . P27A ELISA positive OR parasite ELISA antibody positive AND Known exposure malaria malaria endemic area 16 . P27A ELISA positive AND parasite ELISA antibody positive ( without history stay malaria endemic area ) 17 . Intention travel malaria endemic country study period 18 . Positive HIV , HBV HCV test Phase Ib exclusion criterion 1 . Previously participate malaria vaccine trial 2 . Symptoms , physical sign laboratory value suggestive systemic disorder , include renal , hepatic , cardiovascular , pulmonary , skin , immunodeficiency , psychiatric condition , could interfere interpretation trial result compromise health volunteer 3 . Any clinically significant laboratory abnormality screen blood sample beyond normal range , define clinical trial site 4 . Enrolment clinical trial whole trial period 5 . Intake chronic medication , especially immunosuppressive agent ( steroid , immunomodulating immunosuppressive drug ) thirteen week precede screen visit trial period except topical inhaled steroid 6 . Volunteers unable closely follow social , geographic psychological reason 7 . Previous history drug alcohol abuse interfere normal social function period one year prior enrolment study 8 . Known hypersensitivity vaccine component ( adjuvant peptide ) control vaccine component 9 . Vaccination OR infusion gammaglobulins four ( 4 ) week prior first vaccination six ( 6 ) week third vaccination 10 . Previous vaccination control vaccine 11 . Positive HIV , HCV test HBVsAg positive 12 . Malaria parasite positivity microscopy and/or RDT 13 . Having history confirm malaria episode last five year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>plasmodium falciparum</keyword>
	<keyword>long synthetic peptide</keyword>
	<keyword>antibody</keyword>
	<keyword>T cell</keyword>
	<keyword>cytokine</keyword>
	<keyword>vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>phase 1</keyword>
</DOC>